Skip to main content

Table 2 Results of logistic regression for site of first (s) of recurrence

From: Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study

 

Univariate analysis

OR (95% CI)

P-value

Multivariable analysis

OR (95% CI)

P-value

 

HR-negative vs.

HR-positive

 

HR-negative vs.

HR-positive

 

Local regional

vs. Distant

1.06 (0.71, 1.59)

0.772

1.15 (0.75, 1.76)

0.531

Brain vs. Other

1.75 (1.05, 2.93)

0.033

1.63 (0.95, 2.81)

0.079

Bone vs. Other

0.53 (0.34, 0.82)

0.005

0.53 (0.34, 0.83)

0.005

Lung vs. Other

1.24 (0.76, 2.03)

0.393

1.27 (0.77, 2.09)

0.353

Liver vs. Other

1.38 (0.86, 2.22)

0.188

1.44 (0.89, 2.35)

0.139

  1. Note: HR, Hormone receptor. Adjusting by age at diagnosis, stage and adjuvant trastuzumab.